|
Market Closed -
Euronext Bruxelles
09:25:00 04/09/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 210.60 EUR | -4.58% |
|
-2.73% | -11.74% |
| 01/09 | Global pharma companies that have publicly announced Trump drug pricing agreements | RE |
| 01/09 | White House Cuts Deal to Lower Prescription Drug Prices With Nine Companies | MT |
Company Valuation: UCB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 18,947 | 13,973 | 14,969 | 36,464 | 45,333 | 40,154 | - | - |
| Change | - | -26.25% | 7.12% | 143.6% | 24.32% | -11.43% | - | - |
| Enterprise Value (EV) 1 | 19,807 | 15,973 | 17,146 | 37,918 | 45,326 | 40,459 | 38,346 | 35,787 |
| Change | - | -19.36% | 7.34% | 121.15% | 19.54% | -10.74% | -5.22% | -6.67% |
| P/E | 17.9x | 33.4x | 44.8x | 34.3x | 29.1x | 21x | 17.4x | 14.3x |
| PBR | 2.32x | 1.58x | 1.67x | 3.64x | 4.18x | 3.33x | 2.91x | 2.4x |
| PEG | - | -0.6x | -2.2x | 0x | 0.6x | 1x | 0.8x | 0.7x |
| Capitalization / Revenue | 3.28x | 2.53x | 2.85x | 5.93x | 5.86x | 4.62x | 4.15x | 3.73x |
| EV / Revenue | 3.43x | 2.9x | 3.26x | 6.16x | 5.86x | 4.65x | 3.96x | 3.33x |
| EV / EBITDA | 12.1x | 12.7x | 12.7x | 25.7x | 17.2x | 13.3x | 10.5x | 8.39x |
| EV / EBIT | 15x | 23.7x | 26.1x | 45.4x | 22.6x | 16.5x | 12.8x | 9.8x |
| EV / FCF | 15.6x | 18.4x | 38.5x | 41.2x | 24.6x | 21.2x | 14.5x | 11.5x |
| FCF Yield | 6.42% | 5.43% | 2.6% | 2.43% | 4.06% | 4.72% | 6.89% | 8.71% |
| Dividend per Share 2 | 1.3 | 1.33 | 1.36 | 1.39 | 1.45 | 1.457 | 1.502 | 1.534 |
| Rate of return | 1.3% | 1.81% | 1.72% | 0.72% | 0.61% | 0.69% | 0.71% | 0.73% |
| EPS 2 | 5.6 | 2.2 | 1.76 | 5.61 | 8.2 | 10.01 | 12.13 | 14.74 |
| Distribution rate | 23.2% | 60.5% | 77.3% | 24.8% | 17.7% | 14.5% | 12.4% | 10.4% |
| Net sales 1 | 5,777 | 5,517 | 5,252 | 6,152 | 7,741 | 8,695 | 9,677 | 10,751 |
| EBITDA 1 | 1,641 | 1,260 | 1,349 | 1,476 | 2,636 | 3,052 | 3,644 | 4,267 |
| EBIT 1 | 1,318 | 675 | 657 | 836 | 2,009 | 2,458 | 2,997 | 3,652 |
| Net income 1 | 1,058 | 418 | 343 | 1,065 | 1,558 | 1,931 | 2,325 | 2,816 |
| Net Debt 1 | 860 | 2,000 | 2,177 | 1,454 | -7 | 305.5 | -1,808 | -4,367 |
| Reference price 2 | 100.35 | 73.56 | 78.90 | 192.20 | 238.60 | 210.60 | 210.60 | 210.60 |
| Nbr of stocks (in thousands) | 1,88,812 | 1,89,959 | 1,89,721 | 1,89,720 | 1,89,996 | 1,90,663 | - | - |
| Announcement Date | 24/02/22 | 22/02/23 | 28/02/24 | 27/02/25 | 24/02/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 21.03x | 4.65x | 13.26x | 0.69% | 4.67TCr | |
| 19.17x | 4.48x | 10.55x | 0.47% | 8.27TCr | |
| 20.62x | 4.39x | 13.64x | 2.39% | 6.02TCr | |
| -17.31x | 25.92x | -17.11x | -.--% | 5.81TCr | |
| 35.25x | 12x | 23.01x | -.--% | 4.97TCr | |
| 38.13x | 3.6x | 13.71x | -.--% | 3.26TCr | |
| 56.56x | 3.61x | 27.99x | -.--% | 2.57TCr | |
| 68.2x | 7.25x | 44.11x | -.--% | 2.27TCr | |
| 23.84x | 5.1x | 13.28x | -.--% | 1.65TCr | |
| 67.45x | 41.69x | 59.8x | 0.16% | 1.49TCr | |
| Average | 33.29x | 11.27x | 20.22x | 0.37% | 4.1TCr | |
| Weighted average by Cap. | 24.89x | 9.85x | 14.01x | 0.53% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- UCB Stock
- Valuation UCB
Select your edition
All financial news and data tailored to specific country editions
